دورية أكاديمية
أعرض في EDS

Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.

التفاصيل البيبلوغرافية
العنوان: Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
المؤلفون: Dulal P; Jenner Institute, University of Oxford, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, UK. pawan.dulal@enesipharma.com., Gharaei R; Clothworkers' Centre for Textile Materials Innovation for Healthcare, University of Leeds, Leeds, LS2 9JT, UK., Berg A; Jenner Institute, University of Oxford, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, UK., Walters AA; Jenner Institute, University of Oxford, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, UK., Hawkins N; Oxford Silk Group, ABRG, Department of Zoology, University of Oxford, Oxford, OX2 3RE, UK., Claridge TDW; Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, UK., Kowal K; Nonwovens Innovation and Research Institute Ltd, 169 Meanwood Road, Leeds, LS7 1SR, UK., Neill S; Nonwovens Innovation and Research Institute Ltd, 169 Meanwood Road, Leeds, LS7 1SR, UK., Ritchie AJ; Jenner Institute, University of Oxford, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, UK., Ashfield R; Jenner Institute, University of Oxford, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, UK., Hill AVS; Jenner Institute, University of Oxford, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, UK., Tronci G; Clothworkers' Centre for Textile Materials Innovation for Healthcare, University of Leeds, Leeds, LS2 9JT, UK., Russell SJ; Clothworkers' Centre for Textile Materials Innovation for Healthcare, University of Leeds, Leeds, LS2 9JT, UK.; Nonwovens Innovation and Research Institute Ltd, 169 Meanwood Road, Leeds, LS7 1SR, UK., Douglas AD; Jenner Institute, University of Oxford, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, UK. sandy.douglas@ndm.ox.ac.uk.
المصدر: Scientific reports [Sci Rep] 2021 Oct 22; Vol. 11 (1), pp. 20877. Date of Electronic Publication: 2021 Oct 22.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Vaccine Potency*, Adenoviridae/*genetics , Adenovirus Vaccines/*chemistry , COVID-19/*prevention & control , COVID-19 Vaccines/*therapeutic use, Adenoviruses, Simian ; Biocompatible Materials ; Calorimetry, Differential Scanning ; Glass ; HEK293 Cells ; Humans ; Light ; Magnetic Resonance Spectroscopy ; Materials Testing ; Microscopy, Confocal ; Microscopy, Electron, Scanning ; Polyvinyl Alcohol ; Rabies Vaccines ; Scattering, Radiation ; Spectroscopy, Fourier Transform Infrared ; Sugars/chemistry ; Temperature ; Thermogravimetry ; Trehalose/chemistry
مستخلص: Adenovirus vectors offer a platform technology for vaccine development. The value of the platform has been proven during the COVID-19 pandemic. Although good stability at 2-8 °C is an advantage of the platform, non-cold-chain distribution would have substantial advantages, in particular in low-income countries. We have previously reported a novel, potentially less expensive thermostabilisation approach using a combination of simple sugars and glass micro-fibrous matrix, achieving excellent recovery of adenovirus-vectored vaccines after storage at temperatures as high as 45 °C. This matrix is, however, prone to fragmentation and so not suitable for clinical translation. Here, we report an investigation of alternative fibrous matrices which might be suitable for clinical use. A number of commercially-available matrices permitted good protein recovery, quality of sugar glass and moisture content of the dried product but did not achieve the thermostabilisation performance of the original glass fibre matrix. We therefore further investigated physical and chemical characteristics of the glass fibre matrix and its components, finding that the polyvinyl alcohol present in the glass fibre matrix assists vaccine stability. This finding enabled us to identify a potentially biocompatible matrix with encouraging performance. We discuss remaining challenges for transfer of the technology into clinical use, including reliability of process performance.
(© 2021. The Author(s).)
التعليقات: Erratum in: Sci Rep. 2021 Nov 29;11(1):23361. (PMID: 34845277)
References: J Infect Dis. 2012 Mar 1;205(5):772-81. (PMID: 22275401)
Vaccine. 2011 Sep 22;29(41):7122-4. (PMID: 21651941)
Vaccine. 2010 Feb 25;28(9):2137-48. (PMID: 20044048)
Bull World Health Organ. 2003;81(12):915-6. (PMID: 14997247)
Vaccine. 2019 Nov 8;37(47):6951-6961. (PMID: 31047679)
J Pharm Sci. 2004 Oct;93(10):2458-75. (PMID: 15349956)
Vaccine. 2016 Apr 29;34(20):2296-8. (PMID: 27020712)
Mol Pharm. 2015 Apr 6;12(4):1018-30. (PMID: 25644480)
Bull World Health Organ. 2014 Feb 1;92(2):86-92. (PMID: 24623901)
N Engl J Med. 2016 Apr 28;374(17):1635-46. (PMID: 25629663)
J Pharm Sci. 1999 Oct;88(10):1073-80. (PMID: 10514358)
Hum Vaccin Immunother. 2017 Dec 2;13(12):3020-3032. (PMID: 29083948)
J Pharm Sci. 2013 Jan;102(1):29-33. (PMID: 23136115)
Lancet. 2021 Jan 9;397(10269):99-111. (PMID: 33306989)
J Gen Virol. 2007 Jan;88(Pt 1):1-12. (PMID: 17170430)
Vaccine. 2014 May 19;32(24):2931-8. (PMID: 24662703)
Int J Pharm. 2016 Jun 15;506(1-2):289-301. (PMID: 27130366)
Int J Pharm. 2012 May 10;427(2):145-52. (PMID: 22234038)
Int J Pharm. 2005 Nov 4;304(1-2):29-39. (PMID: 16181753)
J Immunol. 1997 Feb 1;158(3):1268-74. (PMID: 9013969)
PLoS One. 2013 Jul 09;8(7):e67888. (PMID: 23874462)
J Control Release. 1999 Mar 29;58(2):143-51. (PMID: 10053187)
Nat Rev Immunol. 2006 Jan;6(1):21-32. (PMID: 16493425)
Hum Vaccin. 2011 May;7(5):574-5. (PMID: 21422821)
Vaccine. 2017 May 19;35(22):2916-2924. (PMID: 28438408)
Polymers (Basel). 2020 Jul 03;12(7):. (PMID: 32635276)
Sci Transl Med. 2010 Feb 17;2(19):19ra12. (PMID: 20371486)
PLoS One. 2012;7(7):e40385. (PMID: 22808149)
Vaccine. 2010 Jun 17;28(27):4369-75. (PMID: 20444437)
PLoS Negl Trop Dis. 2018 Oct 29;12(10):e0006870. (PMID: 30372438)
PLoS One. 2015 Nov 03;10(11):e0141687. (PMID: 26529238)
N Engl J Med. 2017 Mar 9;376(10):928-938. (PMID: 25426834)
Vaccine. 2015 Dec 22;33(52):7444-51. (PMID: 26476366)
Chem Pharm Bull (Tokyo). 2000 Feb;48(2):283-5. (PMID: 10705520)
Expert Rev Vaccines. 2009 Apr;8(4):447-54. (PMID: 19348560)
Pediatrics. 2001 Jun;107(6):E100. (PMID: 11389298)
Sci Rep. 2015 Nov 18;5:16756. (PMID: 26576856)
J Pharm Sci. 2017 Jul;106(7):1764-1771. (PMID: 28427886)
Pharm Res. 1997 May;14(5):591-5. (PMID: 9165528)
Expert Opin Biol Ther. 2014 May;14(5):601-16. (PMID: 24490585)
Mol Med. 2012 Oct 24;18:1153-60. (PMID: 22735755)
معلومات مُعتمدة: MC_PC_15040 United Kingdom MRC_ Medical Research Council; MC_PC_13073 United Kingdom MRC_ Medical Research Council; 201477/Z/16/Z United Kingdom WT_ Wellcome Trust; BB/M019152/1 United Kingdom BB_ Biotechnology and Biological Sciences Research Council; United Kingdom WT_ Wellcome Trust; MR/P017339/1 United Kingdom MRC_ Medical Research Council; 104750/Z/14 United Kingdom WT_ Wellcome Trust; EP/R013756/1 Engineering and Physical Sciences Research Council
المشرفين على المادة: 0 (Adenovirus Vaccines)
0 (Biocompatible Materials)
0 (COVID-19 Vaccines)
0 (Rabies Vaccines)
0 (Sugars)
9002-89-5 (Polyvinyl Alcohol)
B8WCK70T7I (Trehalose)
تواريخ الأحداث: Date Created: 20211023 Date Completed: 20211115 Latest Revision: 20230301
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8536692
DOI: 10.1038/s41598-021-00065-4
PMID: 34686689
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-021-00065-4